This statistic depicts the market share of orphan drugs that cost patients more than U.S. dollars in 2017. In that year, oncology drugs costing more than dollars per patient annually accounted for nearly ** percent of the total orphan drug market.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
IQVIA. (October 24, 2018). Market share of orphan drugs that cost patients more than $6,000 per year in 2017, by therapy class [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved August 05, 2026, from /statistics/979287/market-share-of-orphan-drugs-more-expensive-than-6k-usd-by-therapy-class/
IQVIA. "Market share of orphan drugs that cost patients more than $6,000 per year in 2017, by therapy class." Chart. October 24, 2018. ÌÇÐÄÆƽâ°æ. Accessed August 05, 2026. /statistics/979287/market-share-of-orphan-drugs-more-expensive-than-6k-usd-by-therapy-class/
IQVIA. (2018). Market share of orphan drugs that cost patients more than $6,000 per year in 2017, by therapy class. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: August 05, 2026. /statistics/979287/market-share-of-orphan-drugs-more-expensive-than-6k-usd-by-therapy-class/
IQVIA. "Market Share of Orphan Drugs That Cost Patients More than $6,000 per Year in 2017, by Therapy Class." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 24 Oct 2018, /statistics/979287/market-share-of-orphan-drugs-more-expensive-than-6k-usd-by-therapy-class/
IQVIA, Market share of orphan drugs that cost patients more than $6,000 per year in 2017, by therapy class ÌÇÐÄÆƽâ°æ, /statistics/979287/market-share-of-orphan-drugs-more-expensive-than-6k-usd-by-therapy-class/ (last visited August 05, 2026)
Market share of orphan drugs that cost patients more than $6,000 per year in 2017, by therapy class [Graph], IQVIA, October 24, 2018. [Online]. Available: /statistics/979287/market-share-of-orphan-drugs-more-expensive-than-6k-usd-by-therapy-class/
